Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Swindells

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 13, 2018
Interest of Youth Living With HIV in Long-Acting AntiretroviralsEthel D Weld, Md Sohel Rana, Ronald H Dallas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2024
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yoninah Cramer, Marjorie Imperial, et al.
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
HIV Clinical Trials|August 9, 2013
Pilot study of younger and older HIV-infected adults using traditional and novel functional assessmentsUriel Sandkovsky, Kevin R Robertson, Jane L Meza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programsAnne F Luetkemeyer, Michelle A Kendall, Mulinda Nyirenda, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2023
Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First TrimesterAmita Gupta, Michael D Hughes, Jorge Leon Cruz, et al.
Human Brain Mapping|November 8, 2014
Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adultsTony W Wilson, Elizabeth Heinrichs-Graham, Katherine M Becker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyAnne F Luetkemeyer, Susan L Rosenkranz, Darlene Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideJacques Grosset, Deepak Almeida, Paul J Converse, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Journal of Acquired Immune Deficiency Syndromes (1999)|November 13, 2018
Interest of Youth Living With HIV in Long-Acting AntiretroviralsEthel D Weld, Md Sohel Rana, Ronald H Dallas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2024
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yoninah Cramer, Marjorie Imperial, et al.
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
HIV Clinical Trials|August 9, 2013
Pilot study of younger and older HIV-infected adults using traditional and novel functional assessmentsUriel Sandkovsky, Kevin R Robertson, Jane L Meza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programsAnne F Luetkemeyer, Michelle A Kendall, Mulinda Nyirenda, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2023
Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First TrimesterAmita Gupta, Michael D Hughes, Jorge Leon Cruz, et al.
Human Brain Mapping|November 8, 2014
Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adultsTony W Wilson, Elizabeth Heinrichs-Graham, Katherine M Becker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyAnne F Luetkemeyer, Susan L Rosenkranz, Darlene Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideJacques Grosset, Deepak Almeida, Paul J Converse, et al.
Pageof 17